Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377] Draft guidance Technology appraisal guidance 10 January 2025 Cladribine for ...

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer TA1021 4 December 2024 4 December 2024 ...

Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments TA1023 11 December 2024 11 December 2024 ...

26 May 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-June 2023.

For further information on the guideline development process, please see how we develop NICE guidelines ...

Tirzepatide's gastrointestinal adverse effects could lead to dehydration and in turn a deterioration in renal function including acute renal failure. Older people and some other groups of people may ...

Following the Technology Appraisal Committee meeting on 13 August 2024, we are consulting with consultees and commentators on the case for extending the statutory 3-month period for funding of ...

Tirzepatide should be thought about as an option for individual people in line with NICE's guideline on overweight and obesity management. The visual summary care pathway has an overview. Table 4 is ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...

Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...

We have a library of over 200 quality standards and a single menu of indicators. They can be used to help define and measure quality in health, public health and social care. They can be used by ...